Cel Sci CVM

NYSE CVM

$1.78 +0.08 (+4.90%)

As of: Sep 29, 2026 · 3:58 PM EDT

Key Stats

Market Cap3.11 Mn

P/E-0.14

Add ratio to table…

About

CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to improving cancer treatment by leveraging the body's immune system. The company focuses on developing immunotherapy product candidates, primarily Multikine for head and neck cancers and L. E. A. P. S. technology for autoimmune diseases like rheumatoid arthritis. Its core activities involve research, preclinical and clinical development, and regulatory planning for these investigational…

CEL-SCI generates revenue through potential future licensing agreements and product sales upon regulatory approval of its product candidates. Currently, the company does not generate significant revenue as none of its product candidates have received FDA or other regulatory approval for human use. Revenue generation is anticipated following successful clinical trials and marketing authorization for Multikine or LEAPS-based therapies.

The company operates through the following segments:

Multikine: This segment focuses on the development of an investigational Phase 3 immunotherapy for the treatment of certain head and neck cancers. Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. It is administered as a neoadjuvant therapy before surgery to stimulate a locoregional immune response against tumors. The Multikine trademark is registered by the Company and subject to FDA review under future regulatory submissions.
L. E. A. P. S. (Ligand Epitope Antigen Presentation System) technology: This segment involves the development of product candidates using the LEAPS platform for potential treatment of rheumatoid arthritis and other autoimmune diseases. The technology modulates immune responses by directing antigen presentation. Several LEAPS-based product candidates are under preclinical development targeting autoimmune conditions.

CEL-SCI holds a distinctive position in the immunotherapy market by focusing on neoadjuvant treatment for head and neck cancer patients with low PD-L1 expression, a population largely underserved by existing checkpoint inhibitors like Keytruda and Opdivo. Its lead candidate, Multikine, demonstrates a clinically meaningful survival benefit in Phase 3 trials, with a 73% five-year overall survival rate versus 45% in the control group. The company's competitive advantage lies in its unique mechanism of action, timing of administration, and strong preclinical and clinical data supporting efficacy and safety.

CEL-SCI serves patients with resectable locally advanced primary squamous cell carcinoma of the head and neck, specifically those with no lymph node involvement and low PD-L1 tumor expression. The company also targets patients with autoimmune diseases such as rheumatoid arthritis through its LEAPS technology platform. These patient populations represent significant unmet medical needs in oncology and immunology.

Investment Thesis

▲ Bull case

CEL-SCI's recent strategic partnership with Amarox in Saudi Arabia represents a critical near-term commercialization pathway that could significantly de-risk the company's trajectory and generate early revenue streams, a factor the market may be underestimating given the focus on the longer-term U.S. confirmatory trial. The agreement provides for a 50/50 net revenue share upon SFDA approval, with Amarox handling local regulatory navigation and distribution, leveraging their #1 ranking in SFDA's shortage and unregistered medicines initiative for three consecutive years (2022-2024) and deep oncology expertise in a region prioritizing breakthrough therapies under Vision 2030. This partnership accelerates access to a defined patient population of approximately 100,000 annually eligible head and neck cancer patients in Saudi Arabia alone, with optional GCC expansion, potentially making Saudi Arabia the first global market to commercialize Multikine. The pursuit of SFDA Breakthrough Medicine Designation, which enables rapid patient access upon approval, creates a near-term catalyst that could yield revenue well before the completion of the U.S. confirmatory trial, reducing reliance on dilutive financing and validating clinical utility in a real-world setting. Management's emphasis on this as a "transformative milestone" and "pivotal shift in commercial trajectory" underscores its strategic importance, yet the market appears to be pricing the stock primarily on the distant U.S. regulatory outcome, overlooking this immediate international avenue for value creation.
The design of CEL-SCI's U.S. FDA Confirmatory Registration trial contains inherent efficiencies that could substantially accelerate the path to approval and commercialization compared to traditional oncology trials, a structural advantage not fully appreciated by investors focused solely on the trial's timeline. The study enrolls only 212 patients selected based on prior Phase 3 data showing 73% long-term survival with Multikine versus 45% without, targeting patients with the best tumor responses to maximize statistical power and minimize risk—a highly enriched population that increases the likelihood of a positive outcome. Crucially, the trial evaluates pre-surgical tumor responses (such as size reduction and physician-downgraded disease) following the three-week Multikine treatment, which management explicitly states could serve as the basis for an accelerated marketing application, potentially enabling earlier commercialization than waiting for full survival data. This surrogate endpoint strategy aligns with FDA pathways for accelerated approval in serious conditions, leveraging the drug's mechanism of action as a neoadjuvant immunotherapy administered before standard treatments weaken the immune system. The market may be underestimating the probability of success in this enriched population and the regulatory flexibility afforded by using early tumor response as a predictor of survival benefit, viewing the trial as a binary long-term outcome event rather than a potential stepping stone to accelerated approval.
CEL-SCI's improving financial discipline and capital efficiency, evidenced by declining operating losses and reduced cash burn despite advancing multiple value-driving milestones, signals a maturing operational model that the market is failing to recognize amid concerns about dilution and going concern warnings. Research and development expenses decreased 13% year-over-year to $15.9 million in fiscal 2025, while general and administrative expenses increased only 9% to $8.9 million, resulting in a net loss reduction of $2.2 million to $25.4 million despite ongoing clinical and regulatory progress. Quarterly trends further show improvement, with net loss narrowing from $7.1 million in Q1 FY25 to $5.5 million in both Q2 and Q3 FY26 (ended December 31, 2025 and March 31, 2026), and basic loss per share declining dramatically from $3.25 to $0.68 and $0.67 respectively—indicating effective cost control even as the company advances the U.S. confirmatory trial, pursues SFDA Breakthrough designation, and closes a $7.2 million equity offering. The ability to reduce losses while increasing strategic initiatives suggests operational leverage and prudent capital allocation, yet the market continues to weigh the stock heavily on historical burn rates and the audit opinion regarding going concern, ignoring the positive inflection in financial metrics that could reduce future dilution needs and extend the cash runway beyond current expectations.

CEL-SCI's recent strategic partnership with Amarox in Saudi Arabia represents a critical near-term commercialization pathway that could significantly de-risk the company's trajectory and generate early revenue streams, a factor the market may be underestimating given the focus on the longer-term U.S. confirmatory trial. The agreement provides for a 50/50 net revenue share upon SFDA approval, with Amarox handling local regulatory navigation and distribution, leveraging their #1 ranking in SFDA's shortage and unregistered medicines initiative for three consecutive years (2022-2024) and deep oncology expertise in a region prioritizing breakthrough therapies under Vision 2030. This partnership accelerates access to a defined patient population of approximately 100,000 annually eligible head and neck cancer patients in Saudi Arabia alone, with optional GCC expansion, potentially making Saudi Arabia the first global market to commercialize Multikine. The pursuit of SFDA Breakthrough Medicine Designation, which enables rapid patient access upon approval, creates a near-term catalyst that could yield revenue well before the completion of the U.S. confirmatory trial, reducing reliance on dilutive financing and validating clinical utility in a real-world setting. Management's emphasis on this as a "transformative milestone" and "pivotal shift in commercial trajectory" underscores its strategic importance, yet the market appears to be pricing the stock primarily on the distant U.S. regulatory outcome, overlooking this immediate international avenue for value creation.
The design of CEL-SCI's U.S. FDA Confirmatory Registration trial contains inherent efficiencies that could substantially accelerate the path to approval and commercialization compared to traditional oncology trials, a structural advantage not fully appreciated by investors focused solely on the trial's timeline. The study enrolls only 212 patients selected based on prior Phase 3 data showing 73% long-term survival with Multikine versus 45% without, targeting patients with the best tumor responses to maximize statistical power and minimize risk—a highly enriched population that increases the likelihood of a positive outcome. Crucially, the trial evaluates pre-surgical tumor responses (such as size reduction and physician-downgraded disease) following the three-week Multikine treatment, which management explicitly states could serve as the basis for an accelerated marketing application, potentially enabling earlier commercialization than waiting for full survival data. This surrogate endpoint strategy aligns with FDA pathways for accelerated approval in serious conditions, leveraging the drug's mechanism of action as a neoadjuvant immunotherapy administered before standard treatments weaken the immune system. The market may be underestimating the probability of success in this enriched population and the regulatory flexibility afforded by using early tumor response as a predictor of survival benefit, viewing the trial as a binary long-term outcome event rather than a potential stepping stone to accelerated approval.
CEL-SCI's improving financial discipline and capital efficiency, evidenced by declining operating losses and reduced cash burn despite advancing multiple value-driving milestones, signals a maturing operational model that the market is failing to recognize amid concerns about dilution and going concern warnings. Research and development expenses decreased 13% year-over-year to $15.9 million in fiscal 2025, while general and administrative expenses increased only 9% to $8.9 million, resulting in a net loss reduction of $2.2 million to $25.4 million despite ongoing clinical and regulatory progress. Quarterly trends further show improvement, with net loss narrowing from $7.1 million in Q1 FY25 to $5.5 million in both Q2 and Q3 FY26 (ended December 31, 2025 and March 31, 2026), and basic loss per share declining dramatically from $3.25 to $0.68 and $0.67 respectively—indicating effective cost control even as the company advances the U.S. confirmatory trial, pursues SFDA Breakthrough designation, and closes a $7.2 million equity offering. The ability to reduce losses while increasing strategic initiatives suggests operational leverage and prudent capital allocation, yet the market continues to weigh the stock heavily on historical burn rates and the audit opinion regarding going concern, ignoring the positive inflection in financial metrics that could reduce future dilution needs and extend the cash runway beyond current expectations.

▼ Bear case

CEL-SCI's continued reliance on dilutive equity offerings to fund operations, despite progress in clinical and regulatory milestones, underscores a persistent inability to achieve self-sustaining financing and poses a significant overhang on shareholder value that the market may be underestimating due to optimistic near-term catalysts. The company raised $28.3 million in gross proceeds during fiscal 2025 through stock sales and recently closed another $7.2 million best-efforts offering at $1.20 per share, adding to a history of frequent dilutive financings that have consistently preceded clinical setbacks or regulatory delays. With net losses still averaging approximately $5.5 million per quarter in recent periods (Q2 and Q3 FY26) and operating cash expenditures of $4.0 million per quarter, the $7.2 million offering provides less than two quarters of operating runway even before accounting for placement agent fees and offering expenses, necessitating further capital raises well before the U.S. confirmatory trial could yield actionable data. The audit opinion citing substantial doubt about the company's ability to continue as a going concern, reiterated in the most recent fiscal year 10-K, remains unmitigated by current progress, as regulatory approvals and commercialization milestones are still contingent and years away, leaving investors exposed to repeated dilution at progressively lower valuations without a clear path to profitability.
The SFDA Breakthrough Medicine Designation pathway in Saudi Arabia, while presented as a near-term commercialization catalyst, carries significant execution risk and uncertainty that management has not adequately addressed, potentially overstating the immediacy and reliability of revenue generation from the Amarox partnership. Although Amarox has a strong track record with the SFDA, including top rankings in shortage and unregistered medicines initiatives, the Breakthrough Medicine Designation is not guaranteed and depends on meeting stringent criteria for addressing unmet medical needs in serious conditions—criteria that Multikine may not satisfy despite its orphan drug status and Phase 3 survival data, which pertains to a specific patient subset not necessarily aligned with SFDA's current priority areas. Even if granted, the designation only accelerates review timelines; it does not guarantee approval, and the company must still complete manufacturing validation, local regulatory submissions, and commercial launch preparations, all of which face potential delays in a foreign regulatory environment with which CEL-SCI has limited direct experience. The 50/50 revenue share further reduces the economic benefit to CEL-SCI, and without disclosed pricing, volume assumptions, or timelines for Saudi Arabia launch, the partnership's financial contribution remains speculative, yet appears to be priced into the stock as a near-term de-risking factor.
The U.S. FDA Confirmatory Registration trial's reliance on enriched patient selection and surrogate endpoints, while potentially efficient, introduces substantial risk of failure to replicate prior Phase 3 results in a real-world setting, a nuance the market may be overlooking in its optimism about the trial's design and management's confidence in accelerated approval pathways. The prior Phase 3 study's 73% versus 45% long-term survival benefit was observed in a randomized controlled trial of 928 patients, but the confirmatory study enrolls only 212 patients specifically selected for having shown the "best type of tumor responses and survival" in that prior study—a highly non-representative cohort that increases vulnerability to statistical fluctuation and reduces generalizability. Should the confirmatory trial fail to demonstrate a statistically significant benefit in this enriched group, it would not only negate the premise for accelerated approval based on tumor response but also raise serious doubts about the robustness of the original Phase 3 findings, potentially triggering a clinical hold or requiring a new, larger trial. Management's emphasis on pre-surgical tumor response as a basis for accelerated application assumes a validated surrogate endpoint relationship that has not been formally agreed upon with the FDA, and the agency retains full discretion to reject such arguments, especially given the historical challenges in immunotherapies where early tumor response does not always correlate with long-term survival benefit in head and neck cancer.

CEL-SCI's continued reliance on dilutive equity offerings to fund operations, despite progress in clinical and regulatory milestones, underscores a persistent inability to achieve self-sustaining financing and poses a significant overhang on shareholder value that the market may be underestimating due to optimistic near-term catalysts. The company raised $28.3 million in gross proceeds during fiscal 2025 through stock sales and recently closed another $7.2 million best-efforts offering at $1.20 per share, adding to a history of frequent dilutive financings that have consistently preceded clinical setbacks or regulatory delays. With net losses still averaging approximately $5.5 million per quarter in recent periods (Q2 and Q3 FY26) and operating cash expenditures of $4.0 million per quarter, the $7.2 million offering provides less than two quarters of operating runway even before accounting for placement agent fees and offering expenses, necessitating further capital raises well before the U.S. confirmatory trial could yield actionable data. The audit opinion citing substantial doubt about the company's ability to continue as a going concern, reiterated in the most recent fiscal year 10-K, remains unmitigated by current progress, as regulatory approvals and commercialization milestones are still contingent and years away, leaving investors exposed to repeated dilution at progressively lower valuations without a clear path to profitability.
The SFDA Breakthrough Medicine Designation pathway in Saudi Arabia, while presented as a near-term commercialization catalyst, carries significant execution risk and uncertainty that management has not adequately addressed, potentially overstating the immediacy and reliability of revenue generation from the Amarox partnership. Although Amarox has a strong track record with the SFDA, including top rankings in shortage and unregistered medicines initiatives, the Breakthrough Medicine Designation is not guaranteed and depends on meeting stringent criteria for addressing unmet medical needs in serious conditions—criteria that Multikine may not satisfy despite its orphan drug status and Phase 3 survival data, which pertains to a specific patient subset not necessarily aligned with SFDA's current priority areas. Even if granted, the designation only accelerates review timelines; it does not guarantee approval, and the company must still complete manufacturing validation, local regulatory submissions, and commercial launch preparations, all of which face potential delays in a foreign regulatory environment with which CEL-SCI has limited direct experience. The 50/50 revenue share further reduces the economic benefit to CEL-SCI, and without disclosed pricing, volume assumptions, or timelines for Saudi Arabia launch, the partnership's financial contribution remains speculative, yet appears to be priced into the stock as a near-term de-risking factor.
The U.S. FDA Confirmatory Registration trial's reliance on enriched patient selection and surrogate endpoints, while potentially efficient, introduces substantial risk of failure to replicate prior Phase 3 results in a real-world setting, a nuance the market may be overlooking in its optimism about the trial's design and management's confidence in accelerated approval pathways. The prior Phase 3 study's 73% versus 45% long-term survival benefit was observed in a randomized controlled trial of 928 patients, but the confirmatory study enrolls only 212 patients specifically selected for having shown the "best type of tumor responses and survival" in that prior study—a highly non-representative cohort that increases vulnerability to statistical fluctuation and reduces generalizability. Should the confirmatory trial fail to demonstrate a statistically significant benefit in this enriched group, it would not only negate the premise for accelerated approval based on tumor response but also raise serious doubts about the robustness of the original Phase 3 findings, potentially triggering a clinical hold or requiring a new, larger trial. Management's emphasis on pre-surgical tumor response as a basis for accelerated application assumes a validated surrogate endpoint relationship that has not been formally agreed upon with the FDA, and the agency retains full discretion to reject such arguments, especially given the historical challenges in immunotherapies where early tumor response does not always correlate with long-term survival benefit in head and neck cancer.

Peer group

Peer Comparison

Companies in the Biotechnology

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	655.56 Bn	31.13	6.69	49.04 Bn
2	ABBV	AbbVie Inc.	470.94 Bn	74.71	7.31	70.82 Bn
3	MRK	Merck & Co., Inc.	367.14 Bn	115.84	5.52	53.91 Bn
4	NVS	Novartis Ag	280.33 Bn	22.35	5.35	37.49 Bn
5	AZN	Astrazeneca Plc	257.78 Bn	23.71	4.20	-0.11 Bn
6	AMGN	Amgen Inc	226.04 Bn	25.83	5.93	57.30 Bn
7	GILD	Gilead Sciences, Inc.	188.89 Bn	-58.39	6.20	26.25 Bn
8	CVM	Cel Sci Corp	0.00 Bn	-0.14	-	-

Cel Sci CVM

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password